The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

Table 1

Baseline characteristics of the population included in the analysis.

Characteristic		UMEC/VI (N = 888)	TIO (N = 875)
Age (years), mean (SD)		62.94 (8.62)	63.29 (8.73)
Male (%)		67.34	68.11
Current smoker at screening, n (%)		51.8	50.74
Smoking pack-years, mean (SD)		45.19 (25.68)	46.16 (27.02)
GOLD stage	II, n (%)	395 (44.48)	389 (44.46)
	III, n (%)	375 (42.23)	376 (42.97)
	IV, n (%)	111 (12.50)	106 (12.11)